MedPath

Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Safety, Tolerability and Pharmacodynamics of BIIX 1 XX in Healthy Young Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
Drug: BIIX 1 XX - single rising dose
First Posted Date
2014-07-25
Last Posted Date
2014-10-29
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
24
Registration Number
NCT02199873

Safety, Tolerability and Pharmacodynamics of BIIF 1149 BS in Healthy Young Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BIIF 1149 BS - single rising doses
Drug: Placebo
First Posted Date
2014-07-25
Last Posted Date
2014-07-25
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
64
Registration Number
NCT02199899

Micardis®. Observational Study in Patients With Essential Hypertension

Completed
Conditions
Hypertension
Interventions
Drug: Low dose of Telmisartan, once daily
Drug: High dose of Telmisartan, once daily
First Posted Date
2014-07-25
Last Posted Date
2014-07-25
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
4532
Registration Number
NCT02200094

A Trial Comparing MICARDIS® (Telmisartan) and COZAAR® / LORZAAR® (Losartan) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (ABPM)

Phase 4
Completed
Conditions
Hypertension
Interventions
Drug: High dose of COZAAR® / LORZAAR®, once daily
Drug: High dose of MICARDIS®, once daily
Drug: Low dose of COZAAR® / LORZAAR®, once daily
Drug: Low dose of MICARDIS®, once daily
Drug: Placebo
First Posted Date
2014-07-25
Last Posted Date
2014-07-25
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
387
Registration Number
NCT02200653

Study to Determine Tolerability After Intravenous Administration of BIBN 4096 BS in Healthy Male and Female Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BIBN 4096 BS - in single rising doses
Drug: Placebo
First Posted Date
2014-07-23
Last Posted Date
2014-07-29
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
55
Registration Number
NCT02198352

Dose Extension Study of BIIX 1 XX in Healthy Young Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
Drug: BIIX 1 XX inhalation solution
First Posted Date
2014-07-23
Last Posted Date
2014-07-23
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
54
Registration Number
NCT02198287

Single Rising Dose Tolerability Study of BIBN 4096 BS in Healthy Male and Female Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
Drug: BIBN 4096 BS- in single rising doses
First Posted Date
2014-07-23
Last Posted Date
2014-07-23
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
32
Registration Number
NCT02198326

Efficacy, Safety, Tolerability and Pharmacokinetics of BIBN 4096 BS Versus Placebo in the Treatment of a Single Attack of Acute Migraine Headache

Phase 2
Completed
Conditions
Migraine Disorders
Interventions
Drug: Placebo
First Posted Date
2014-07-23
Last Posted Date
2014-07-23
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
126
Registration Number
NCT02198339

A Multiple Increasing Dose Safety and Tolerability Study After Inhalation Administration of BIIX 1 XX in Healthy Male Volunteers

Phase 1
Terminated
Conditions
Healthy
Interventions
Drug: BIIX 1 XX - D1
Drug: BIIX 1 XX - D2
Drug: Placebo
Drug: BIIX 1 XX - D3
First Posted Date
2014-07-23
Last Posted Date
2018-08-31
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
8
Registration Number
NCT02198313

Intravenous BIBH 1 in Patients With Metastatic Colorectal Cancer

Phase 2
Completed
Conditions
Colorectal Neoplasms
Interventions
First Posted Date
2014-07-23
Last Posted Date
2014-07-23
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
25
Registration Number
NCT02198274
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy